Evaluating Teclistamab, Daratumumab, and Pomalidomide in Multiple Myeloma

Anita D'Souza, MD, professor of medicine at the Medical College of Wisconsin, provides an overview of the abstract that she presented on at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition regarding safety and efficacy data for patients with multiple myeloma treated with the combination of teclistamab-cqyv (Tecvayli), daratumumab (Darzalex), and pomalidomide (Pomalyst) in 2 phase studies: MajesTEC-2 (NCT04722146) and TRIMM‑2 (NCT04108195).

Transcription:

0:10 | So, the ASH abstract that covered [data from the] MajesTEC-2 and TRIMM-2 [studies] was a very specific cohort of patients on these 2 trials that were treated with a teclistamab, daratumumab, and pomalidomide combination. So, this was a pooled analysis of patients that received this triple drug combination across these 2 trials. These trials had enrolled patients between 2020 and 2021, so we had a longer follow-up for patients. When combined, it was a little over 2 years, which was a little bit longer for the patients in TRIMM-2 and a little shorter for the patients in MajesTEC-2.

0:52 | But what we saw was, put in the context of what these 2 trials eligibility criteria were, for MajesTEC-2, these were patients [with myeloma] who had received 1 to 3 prior lines of therapy. For TRIMM-2, these were patients who had 3 or more prior lines of therapy. So, there was definitely a more heavily pretreated patient population for TRIMM-2 compared with the MajesTEC-2 cohort. We had a total of 27 patients that received this triple drug combination, 17 from MajesTEC-2 and 10 from TRIMM-2.

This transcription was edited for clarity with AI.

REFERENCE:

1. D'Souza A, Costa LJ, San-Miguel JF, et al. Teclistamab, daratumumab, and pomalidomide in patients with relapsed/refractory multiple myeloma: results from the Majestec-2 cohort a and Trimm‑2 studies. Blood. 2024;144(suppl 1):495. doi:10.1182/blood-2024-202713